Kora Saúde Participações S.A.

As of December 31, 2024, Kora Saúde Participações S.A. has 76.90M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 0.28, and the price-to-book ratio stands at -2.93.

As of December 31, 2024, Kora Saúde Participações S.A. trades at an EV/EBITDA multiple of 13.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.13 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Kora Saúde Participações S.A. trades at an EV/FCF ratio of 12.48, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2024, Kora Saúde Participações S.A. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 325.18, indicating elevated leverage, while an interest coverage ratio of 0.74 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -3.93, reflecting losses generated across the asset base. Inventory turnover of 23.21 indicates how many times Kora Saúde Participações S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2024, Kora Saúde Participações S.A. posted a gross margin of 20.03, reflecting its pricing power and cost economics. The operating margin of 11.67 and net profit margin of -8.22 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. The dividend payout ratio of -1.99 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -10.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.35, meaning Kora Saúde Participações S.A. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2024, Kora Saúde Participações S.A. has an Altman Z-Score of 1.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.